News Release

View printer-friendly version
<< Back

DURECT Corporation Presenting at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference

CUPERTINO, Calif., March 29, 2005 /PRNewswire-FirstCall via COMTEX/ -- DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference. The conference is taking place April 4-5th at The Millennium Broadway Hotel in New York City, New York. James E. Brown, DVM, President and Chief Executive Officer will be presenting at the conference on Monday, April 4th at 2:15 p.m. Eastern Time.

There will be a live webcast of the presentation from the Conference. The webcast will be available on DURECT's website under the Event Calendar section of "Investor Relations." The presentation will also be available for replay on DURECT's website for a period of up to 30 days after the conference.


DURECT Corporation is an emerging specialty pharmaceutical company focused on the development of pharmaceutical systems based on its proprietary drug delivery platform technologies that treat chronic debilitating diseases and enable biotechnology products. These platform technologies include the SABER(TM) Delivery System (a patented and versatile depot injectable useful for protein and small molecule delivery), the ORADUR(TM) sustained release oral gel-cap technology (an oral sustained release technology with several potential abuse deterrent properties), the DURIN(TM) Biodegradable Implant (drug-loaded implant system), the TRANSDUR(TM) transdermal technology and the MICRODUR(TM) Biodegradable Microparticulates (microspheres injectable system). DURECT also collaborates with pharmaceutical companies to develop and commercialize proprietary and enhanced pharmaceutical products based on its technologies. DURECT has five disclosed on-going development programs of which four are in collaboration with pharmaceutical partners. Additional information about DURECT is available at

NOTE: SABER(TM), ORADUR(TM), DURIN(TM), TRANSDUR(TM) and MICRODUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners.


Schond L. Greenway
Executive Director, IR and Strategic Planning of DURECT Corporation